Oxford BioDynamics (LON:OBD) Trading Down 11.6% – Time to Sell?

Oxford BioDynamics Plc (LON:OBD)’s stock price dropped 11.6% on Wednesday . The company traded as low as GBX 0.94 ($0.01) and last traded at GBX 0.97 ($0.01). Approximately 4,693,215 shares traded hands during trading, an increase of 14% from the average daily volume of 4,110,961 shares. The stock had previously closed at GBX 1.10 ($0.01).

Oxford BioDynamics Price Performance

The stock has a market cap of £3.11 million, a PE ratio of -16.63 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The firm’s 50 day moving average price is GBX 1.25 and its two-hundred day moving average price is GBX 3.95.

Insider Activity at Oxford BioDynamics

In other Oxford BioDynamics news, insider David Holbrook bought 49,653 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were acquired at an average cost of GBX 1 ($0.01) per share, for a total transaction of £496.53 ($606.26). 16.78% of the stock is currently owned by corporate insiders.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.